title: Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study.
abstract: The aim was to investigate the efficacy of neoadjuvant docetaxel-cisplatin and identify prognostic factors for outcome in locally advanced stage IIIA (pN2 by mediastinoscopy) non-small-cell lung cancer (NSCLC) patients. In all, 75 patients (from 90 enrolled) underwent tumour resection after three 3-week cycles of docetaxel 85 mg m-2 (day 1) plus cisplatin 40 or 50 mg m-2 (days 1 and 2). Therapy was well tolerated (overall grade 3 toxicity occurred in 48% patients; no grade 4 nonhaematological toxicity was reported), with no observed late toxicities. Median overall survival (OS) and event-free survival (EFS) times were 35 and 15 months, respectively, in the 75 patients who underwent surgery; corresponding figures for all 90 patients enrolled were 28 and 12 months. At 3 years after initiating trial therapy, 27 out of 75 patients (36%) were alive and tumour free. At 5-year follow-up, 60 and 65% of patients had local relapse and distant metastases, respectively. The most common sites of distant metastases were the lung (24%) and brain (17%). Factors associated with OS, EFS and risk of local relapse and distant metastases were complete tumour resection and chemotherapy activity (clinical response, pathologic response, mediastinal downstaging). Neoadjuvant docetaxel-cisplatin was effective and tolerable in stage IIIA pN2 NSCLC, with chemotherapy contributing significantly to outcomes.
authors.affiliation: Clinic of Medical Oncology, Hospital of Fribourg, 1700 Fribourg, Switzerland. betticherd@hopcantfr.ch
authors.forename: D C
authors.initials: DC
authors.lastname: Betticher
authors.forename: S-F
authors.initials: SF
authors.lastname: Hsu Schmitz
authors.forename: M
authors.initials: M
authors.lastname: Tötsch
authors.forename: E
authors.initials: E
authors.lastname: Hansen
authors.forename: C
authors.initials: C
authors.lastname: Joss
authors.forename: C
authors.initials: C
authors.lastname: von Briel
authors.forename: R A
authors.initials: RA
authors.lastname: Schmid
authors.forename: M
authors.initials: M
authors.lastname: Pless
authors.forename: J
authors.initials: J
authors.lastname: Habicht
authors.forename: A D
authors.initials: AD
authors.lastname: Roth
authors.forename: A
authors.initials: A
authors.lastname: Spiliopoulos
authors.forename: R
authors.initials: R
authors.lastname: Stahel
authors.forename: W
authors.initials: W
authors.lastname: Weder
authors.forename: R
authors.initials: R
authors.lastname: Stupp
authors.forename: F
authors.initials: F
authors.lastname: Egli
authors.forename: M
authors.initials: M
authors.lastname: Furrer
authors.forename: H
authors.initials: H
authors.lastname: Honegger
authors.forename: M
authors.initials: M
authors.lastname: Wernli
authors.forename: T
authors.initials: T
authors.lastname: Cerny
authors.forename: H-B
authors.initials: HB
authors.lastname: Ris
mesh_terms: D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D000077143:Docetaxel; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011379:Prognosis; D012008:Recurrence; D018570:Risk Assessment; D015996:Survival Rate; D043823:Taxoids / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin